Vaxelis Market Report 2026: Epidemiology, Pipeline Analysis, Market Insights & Forecasts

The growth in the historic period can be attributed to expansion of childhood immunization coverage, inclusion of combination vaccines in public health programs, improvements in vaccine manufacturing scalability, rising government procurement of vaccines, increased awareness of preventable diseases.

The growth in the forecast period can be attributed to expansion of global vaccination initiatives, rising demand for simplified immunization regimens, increasing investments in vaccine innovation, growing focus on supply chain resilience, expansion of immunization access in emerging markets. Major trends in the forecast period include increasing adoption of combination vaccines, rising emphasis on pediatric immunization programs, growing demand for single-dose multivalent vaccines, expansion of national vaccination schedules, enhanced focus on cold-chain vaccine management.

The rising pediatric population is expected to drive the growth of the Vaxelis market going forward. The pediatric population includes children from birth through adolescence. This population is growing due to improved healthcare, better nutrition, enhanced maternal care, reduced infant mortality, and increased awareness of child health and vaccination programs. Vaxelis offers protection against six serious diseases in a single vaccine, reducing the need for multiple separate immunizations. For instance, in December 2024, according to Child Stats, a US-based federal interagency forum for child and family statistics, the United States had 72.5 million children in 2022, with projections indicating an increase to 78.2 million by 2050. Therefore, the rising pediatric population is driving the growth of the Vaxelis market.

The increase in healthcare expenditure is expected to propel the growth of the Vaxelis market. Healthcare expenditure encompasses the financial resources invested by governments, private insurers, and individuals to improve and expand medical services. Higher healthcare spending supports Vaxelis by funding vaccination programs, increasing access to immunization, and promoting public health initiatives that raise awareness and improve vaccine distribution, thereby boosting adoption and demand. For instance, in June 2025, according to Health Foundation, a UK-based independent charity, the planned Department of Health and Social Care spending is projected to grow from $265.4 billion (£215.6 billion) in 2025/26 to $303.9 billion (£246.8 billion) in 2028/29, reflecting a real-terms increase of 2.8% per year. Therefore, rising healthcare expenditure is driving the growth of the Vaxelis market.

The rising prevalence of hepatitis B cases is expected to propel the growth of the Vaxelis market. Hepatitis B is a viral infection caused by the hepatitis B virus (HBV) that affects the liver and can lead to acute and chronic conditions, including liver cirrhosis and liver cancer. The growing number of hepatitis B cases is due to insufficient vaccination coverage, weak healthcare systems, high-risk behaviors such as needle sharing, and limited public awareness about prevention. Vaxelis provides immunity against hepatitis B through the inclusion of the hepatitis B surface antigen, helping prevent infection and its associated complications. For instance, in April 2025, the Centers for Disease Control and Prevention (US-based) reported 2,214 new acute hepatitis B cases in 2023, along with 1,769 hepatitis B-related deaths. Therefore, the increasing prevalence of hepatitis B is driving the growth of the Vaxelis market.

Major companies operating in the vaxelis market are Merck & Co. Inc., Sanofi S.A.

North America was the largest region in the vaxelis market in 2025. The regions covered in the vaxelis market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the vaxelis market report are Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada.

Tariffs are impacting the vaxelis market by increasing costs of imported vaccine raw materials, sterile packaging components, cold-chain equipment, and biologics manufacturing inputs. Government immunization programs and hospital procurement systems in North America and Europe are most affected due to cross-border sourcing of vaccine components, while developing regions face higher distribution costs. These tariffs are influencing vaccine pricing and procurement timelines. However, they are also driving domestic vaccine manufacturing investments, localized fill-finish operations, and long-term strengthening of national immunization supply chains.

The vaxelis market research report is one of a series of new reports that provides vaxelis market statistics, including vaxelis industry global market size, regional shares, competitors with a vaxelis market share, detailed vaxelis market segments, market trends and opportunities, and any further data you may need to thrive in the vaxelis industry. This vaxelis market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Vaxelis is a six-in-one vaccine that protects against diphtheria, tetanus, whooping cough, polio, *Haemophilus influenzae* type B, and hepatitis B. It is primarily administered to infants and children as part of routine vaccination programs.

The primary indications for Vaxelis include pertussis, diphtheria, and tetanus. Pertussis is a highly contagious respiratory infection caused by *Bordetella pertussis*, marked by severe coughing fits that can lead to breathing difficulties. Vaxelis protects against pertussis by stimulating the immune system to prevent infection and reduce symptom severity in children. It is distributed through hospitals, retail pharmacies, and government supply programs, and is used by end users including hospitals, clinics, ambulatory care centers, and home care settings.

The vaxelis market consists of sales of active ingredients and antigens, vaccine administration supplies, and cold chain equipment. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.